2 news items
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
SAGE
25 Apr 24
the European Medicines Agency (EMA) for the potential treatment of Huntington's Disease. Dalzanemdor has also been awarded an Innovation Passport
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
ADXN
BIVI
EVO
24 Apr 24
shares is at $1.8 billion. The company's, Q4 earnings came out today.
Innovative Eyewear
- Prev
- 1
- Next